Publicacións nas que colabora con Joaquín Díaz Mediavilla (18)

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))

    Leukemia

2012

  1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  2. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2011

  1. Invasive fungal infections in onco-haematology: A spanish perspective

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172

  2. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2010

  1. Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología

    Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

2005

  1. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

    Annals of Oncology, Vol. 16, Núm. 4, pp. 625-633

2003

  1. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome

    Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751

2002

  1. Hematopoietic stem cell transplantation in patients or from donors with hepatitis B or C virus infection: Review and recommendations

    Medicina Clinica

2001

  1. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    Journal of Clinical Oncology, Vol. 19, Núm. 5, pp. 1395-1404

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140

1997

  1. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 34-41

  2. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica. Registro Español de Trasplante en Mieloma.

    Sangre, Vol. 42 Suppl 1, pp. 38-41

1993

  1. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group

    Annals of Hematology, Vol. 67, Núm. 3, pp. 111-114